DVAX up 10% @ 3.58 > Dynavax Technologies, Valneva Team Up for Covid-19 Vaccine Program
6:44 am ET April 23, 2020 (Dow Jones) Print
By Chris Wack
Valneva SE and Dynavax Technologies Corp. said they are collaborating to initiate a vaccine program for Covid-19.
Valneva is providing its platform for IXIARO, its commercial vaccine product indicated for active immunization for the prevention of Japanese encephalitis. This platform operates on a highly purified Vero-cell based, inactivated, whole virus strategy for vaccine development.
Dynavax is providing technical expertise and its proprietary toll-like receptor 9 agonist adjuvant, CpG 1018, the adjuvant used in Hepatitis B Vaccine Recombinant, an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration. Dynavax developed CpG 1018 to provide an increased vaccine immune response. CpG 1018 provides a well-developed technology and a significant safety database, potentially accelerating the development and large-scale manufacturing of a COVID-19 vaccine.
Valneva will use its Biosafety Level 3 laboratory capabilities to rapidly leverage its large scale, Vero-based, viral Good Manufacturing Practice manufacturing facility in Livingston, Scotland.
News 
Market Data 
Discover 
